Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

Similar articles for PubMed (Select 15613690)

1.

Mantle cell lymphoma: at last, some hope for successful innovative treatment strategies.

Fisher RI.

J Clin Oncol. 2005 Feb 1;23(4):657-8. Epub 2004 Dec 21. No abstract available.

2.

The role of bortezomib in the treatment of lymphoma.

Barr P, Fisher R, Friedberg J.

Cancer Invest. 2007 Dec;25(8):766-75. Review.

PMID:
18058474
3.

Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II.

O'Connor O, Wright J, Moskowitz CH, Muzzy J, MacGregor-Cortelli B, Hamlin P, Straus D, Trehu E, Schenkein DP, Zelenetz AD.

J Natl Compr Canc Netw. 2004 Nov;2 Suppl 4:S21-2.

PMID:
19791425
4.

Bortezomib: putting mantle cell lymphoma on death row.

Wei AH, Roberts AW.

Leuk Lymphoma. 2008 Apr;49(4):657-8. doi: 10.1080/10428190801942378. Review. No abstract available.

PMID:
18398731
5.

Treatment of mantle cell lymphoma: targeting the microenvironment.

Drach J, Seidl S, Kaufmann H.

Expert Rev Anticancer Ther. 2005 Jun;5(3):477-85. Review.

PMID:
16001955
6.

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

O'Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, Straus D, Portlock C, Hamlin P, Choi E, Dumetrescu O, Esseltine D, Trehu E, Adams J, Schenkein D, Zelenetz AD.

J Clin Oncol. 2005 Feb 1;23(4):676-84. Epub 2004 Dec 21.

7.

Captivating bortezomib: an active but still mysterious drug.

Di Raimondo F, Conticello C.

Leuk Res. 2010 Apr;34(4):411-2. doi: 10.1016/j.leukres.2009.09.021. Epub 2009 Oct 12. No abstract available.

PMID:
19819547
8.

Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial.

O'Connor OA, Moskowitz C, Portlock C, Hamlin P, Straus D, Dumitrescu O, Sarasohn D, Gonen M, Butos J, Neylon E, Hamelers R, Mac-Gregor Cortelli B, Blumel S, Zelenetz AD, Gordon L, Wright JJ, Vose J, Cooper B, Winter J.

Br J Haematol. 2009 Apr;145(1):34-9. doi: 10.1111/j.1365-2141.2008.07466.x. Epub 2009 Feb 6.

PMID:
19220284
9.

Targeting the proteasome in mantle cell lymphoma: a promising therapeutic approach.

Bogner C, Peschel C, Decker T.

Leuk Lymphoma. 2006 Feb;47(2):195-205. Review.

PMID:
16321849
10.

Bortezomib in mantle cell lymphoma.

Suh KS, Goy A.

Future Oncol. 2008 Apr;4(2):149-68. doi: 10.2217/14796694.4.2.149. Review.

PMID:
18407730
11.

Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.

Leonard JP, Furman RR, Coleman M.

Int J Cancer. 2006 Sep 1;119(5):971-9. Review.

PMID:
16557600
12.

[Bortezomib].

Simons S, Scheulen ME, Jaehde U.

Dtsch Med Wochenschr. 2006 Feb 3;131(5):214-8. Review. German. No abstract available.

PMID:
16440269
13.

Mantle cell lymphomas.

Moskowitz CH.

Clin Adv Hematol Oncol. 2005 Nov;3(11):suppl 6-7. Review. No abstract available.

PMID:
16491629
14.

Can survivin expression predict the response to bortezomib in cases with mantle cell lymphoma?

Paydas S.

Leuk Lymphoma. 2006 Nov;47(11):2412-3. No abstract available.

PMID:
17107919
15.

Bortezomib for the treatment of mantle cell lymphoma.

Kane RC, Dagher R, Farrell A, Ko CW, Sridhara R, Justice R, Pazdur R.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5291-4.

16.

Successful T-cell acute lymphoblastic leukemia treatment with proteasome inhibitor bortezomib based on evaluation of nuclear factor-κB activity.

Hu X, Xu J, Sun A, Shen Y, He G, Guo F.

Leuk Lymphoma. 2011 Dec;52(12):2393-5. doi: 10.3109/10428194.2011.593271. Epub 2011 Jul 12. No abstract available.

PMID:
21745166
17.

Managing patients with multiple myeloma and mantle cell lymphoma: where are we now?

Amen K.

ONS Connect. 2007;22(8 Suppl):63-4. No abstract available.

PMID:
17824570
18.

From orbital hybridization to chemotherapeutics neutralization.

Ghosh N, Emadi A.

Blood. 2009 Jun 11;113(24):6262. doi: 10.1182/blood-2009-03-209148. No abstract available.

19.

Missing the target: ubiquitin ligase drugs stall.

Garber K.

J Natl Cancer Inst. 2005 Feb 2;97(3):166-7. No abstract available.

20.

[Pharmacological and clinical profile of Bortezomib (Velcade)].

Fujii H, Kotobuki Y, Nomura S, Harada Y.

Nihon Yakurigaku Zasshi. 2007 Nov;130(5):421-9. Review. Japanese. No abstract available.

PMID:
18000359
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk